A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC

NCT07422753 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma (HCC)

Interventions

DRUG: placebo
DRUG: CTLA-4 Antibody(ipilimumab N01)

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University